Dr. Ruley is currently Professor of Pathology, Microbiology and Immunology at the Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
He received Bachelor’s degree from the Stanford University, Ph.D. degree from the University of North Carolina, Chapel Hill, in 1980, and post-doctoral from the Imperial Cancer Research Fund in London, England. He has held Staff Scientist position at the Cold Spring Harbor Laboratory, and Assistant and Associate Professor at the Massachusetts Institute of Technology.?
His research program has made significant contributions concerning basic mechanism of cell transformation by viral and cellular oncogenes, interactions between oncogenes and tumor suppressors, mammalian functional genomics, and the field of TSDT. Dr. Ruley has served on a number of advisory panels for both government and industry. He is co-founder of two biotech companies and holds two U.S patents. Dr. Ruley has published more than one hundred of research articles in peer-reviewed journals and was a mentor of Dr. Daewoong Jo’s doctoral study at Vanderbilt.
He serves as head director of administration & planning headquarter and as COO at Cellivery. Mr. Kie earned BA from Yonsei University in Management and MBA from University of Michigan (Ann Arbor, Michigan, USA). Prior to joining Cellivery, he spent over 15 years at Hyundai Group, where he successfully served as a director of strategic planning division, financial strategy team. In this role, Mr. Kie was responsible for investment reports, fund raising, and equity management. Now, he dedicated himself in Cellivery’s future strategies development and supports all aspects of business development.
Dr. Choi joined Cellivery in 2014 and currently serves as chief scientist of New Drug Develoment & Business Develoment and CSO. She received her Bachelor degree in Biology at Kyunghee University, and obtained her Master and Ph.D. degrees in Cell Biology at Ewha Womans University, Seoul, Korea. In the two following years, she conducted her postdoctoral fellowship at the Research Center for Homeostasis of Ewha Womans University. Her research interests are focused on discovering new drugs to treat various cancers.
Dr. Cha joined Cellivery in 2016 and currently serves as senior scientist of Neurodegenerative Disease Team. He received his Bachelor’s and Master degree in Biology at Inha University, and obtained his Ph.D. degrees in Cell Biology at Vanderbilt University, TN, USA. In the five following years, he conducted her postdoctoral fellowship at the NIH. His research interests are focused on research of Lymphangiogenesis.
Dr. Lee has joined Cellivery in 2015 and currently serves as Director of Genome Engineering and Cell Fate Regulating Team. She received her Bachelor’s and Ph.D. degrees in Cell Biology at Chonnam National University and has experience in research of cardiovascular disease at the KNIH.